Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 0.59 |
| ▸ | QPCT | Q16769 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL809874 | 1.00 | NAMPT (1.00) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL809933 | 1.00 | NAMPT (1.00) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL810340 | 1.00 | NAMPT (1.00) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL809897 | 1.00 | NAMPT (1.00) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL810114 | 1.00 | NAMPT (1.00) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| Chs-828 SCHEMBL23924547 | 1.00 | NAMPT (1.00) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| Chs-828 SCHEMBL2672576 | 1.00 | NAMPT (1.00) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| Chs-828 SCHEMBL7148795 | 0.99 | NAMPT (0.98) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| Chs-828 SCHEMBL7142973 | 0.99 | NAMPT (0.98) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8916372 | 0.90 | NAMPT (0.82) | NAMPTCYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | claimed |
| EP-1411984-B1 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA AS (DK) | 2008-05-07 | — | — | EP | claimed |
| EP-1411984-A2 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | Leo Pharma A/S (DK) | 2004-04-28 | — | — | EP | claimed |
| WO-2002094322-A2 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES CONTAINING CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | claimed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | DISARM THERAPEUTICS, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2023162840-A1 | ASSESSMENT OF ADVERSE EVENTS INDUCED BY ADMINISTRATION OF ANTITUMOR DRUG AND/OR IMMUNE CHECKPOINT INHIBITOR BY USING DISEASE MODEL MOUSE | 国立大学法人東北大学 | 2023-08-31 | — | — | WO | disclosed |
| US-20220160688-A1 | INHIBITION OF NAMPT AND/OR SARM1 FOR THE TREATMENT OF AXONAL DEGRADATION | THE JOHNS HOPKINS UNIVERSITY | 2022-05-26 | — | — | US | disclosed |
| EP-2394649-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDYL CYANOGUANIDINES, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-12-14 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1411984-B1 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA AS (DK) | 2008-05-07 | — | — | EP | disclosed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| EP-1411984-A2 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES WHICH CONTAINS CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | Leo Pharma A/S (DK) | 2004-04-28 | — | — | EP | disclosed |
| WO-2002094322-A2 | COMBINATION MEDICAMENT FOR TREATMENT OF NEOPLASTIC DISEASES CONTAINING CYANOGUANIDINE IKK INHIBITORS AND A SECOND ANTI-NEOPLASTIC DRUG | LEO PHARMA A/S (DK) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083114-B2 | Inhibitors of SARM1 in combination with neuro-protective agents | SARM1, SMN1; SMN2, SARNP | NAMPT 813/4885CYP3A4 4851/4885CYP2D6 4825/4885 |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | NAMPT 3566/4885CYP3A4 3023/4885CYP2D6 3049/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | NAMPT 2023/4885CYP3A4 3596/4885CYP2D6 3517/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | NAMPT 3566/4885CYP3A4 3023/4885CYP2D6 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.